Creo Medical Group plc
("Creo" the "Company" or the "Group")
Exercise of Options, PDMR Dealing, Issue of Equity and TVR
Creo Medical Group plc (AIM: CREO), the medical device company, focused on the emerging field of surgical endoscopy, announces that it has received notice of exercise of options ("Options") under the Company's share option scheme from John Bradshaw, senior independent non-executive director and a PDMR, to subscribe for a total of 105,947 new ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares"). 27,000 of the Options are to be exercised at a price of £0.21389 per Ordinary Share, and 78,947 Options are to be exercised at a price of £0.76 per Ordinary Share.
Application has been made for the admission of 105,947 new Ordinary Shares to trading on AIM ("Admission"). It is expected that Admission will occur at 8:00 a.m. on 10 August 2022. Following the exercise of the Options, Mr Bradshaw will hold 105,947 Ordinary Shares in the Company representing approximately 0.06 percent. of the Company's issued share capital.
Mr Bradshaw has confirmed his current intention to hold the Ordinary Shares and does not intend to sell any Ordinary Shares to meet any tax liability arising on the exercise of the Options. Following this transaction, Mr Bradshaw will hold no share options in the Company.
Following Admission, the Company will have 181,527,885 Ordinary Shares in issue with voting rights attached. The Company has no shares in treasury; therefore upon, and subject to, registration, the total number of voting rights in Creo will be 181,527,885. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure and Transparency Rules.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1. Details of PDMR | ||||||||
| a) | Name | John Bradshaw | ||||||
| b) | Position / status | Senior Independent Non-Executive Director | ||||||
| c) | Initial notification / amendment | Initial notification | ||||||
| 2. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||
| a) | Description of the financial instrument | Ordinary Shares | ||||||
| b) | Nature of the transaction | Exercise of share options
| ||||||
| c) | Price(s) and volume(s) |
| ||||||
| d) | Aggregated information
Aggregated volume Price |
105,947 £65,774.75 | ||||||
| e) | Date of the transaction | 2022-08-03 | ||||||
| f) | Place of the transaction | Off Market | ||||||
Enquiries:
| Creo Medical Group plc | |
| Richard Rees (CFO) | +44 (0)1291 606 005 |
| | |
| Cenkos Securities plc | +44 (0)20 7397 8900 |
| Stephen Keys / Camilla Hume (NOMAD) | |
| Michael Johnson / Russell Kerr (Joint Broker) | |
| | |
| Numis Securities Limited (Joint Broker) | +44 (0)20 7260 1000 |
| Freddie Barnfield / James Black / Duncan Monteith | |
| | |
| Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com |
| Paul McManus / Sam Allen / Phillip Marriage | Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082 |
About Creo Medical
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.
For more information, please refer to the website www.creomedical.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
